Reining in cancer
Combining trastuzumab and ZD1839 has been shown to be more effective in inhibiting breast cancer cell growth than using either treatment alone. The findings suggest a potential new approach for treating multiple types of cancers, including those with HER2 and EGFR gene mutations.